T1	Participants 92 98	humans
T2	Participants 123 147	Toronto General Hospital
T3	Participants 478 533	patients with gastric, pancreatic and colorectal cancer
T4	Participants 715 784	patients with malignant melanoma and stage IV carcinoma of the breast
T5	Participants 823 869	patients with advanced gastrointestinal cancer
